araag2/HINT huggingface dataset:
Clinical trial NCT00002593 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: fluorouracil, leucovorin calcium, levamisole hydrochloride
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, C1CN2C[C@@H](N=C2S1)C1=CC=CC=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically proven resectable stage II or III adenocarcinoma of
        the colon Caudal margin of the primary tumor must lie above the peritoneal reflection Must
        have pathologic confirmation of either N1-3 (stage III), or if N0, must have T3-T4 (stage
        II) with bowel obstruction or perforation Obstruction documented as: At least 75% colon or
        small bowel obstruction on x-ray and/or endoscopy Significant bowel dilatation surgically
        documented Significant obstruction described in the pathology report Perforation documented
        by gross operative/pathologic evidence of a colon wall defect with associated abscess or
        peritonitis Complete en bloc resection by laparotomy required No laparoscopic colectomy
        without prior surgery on protocol SWOG-9411 No gross or microscopic residual disease No
        distant peritoneal metastases (stage IV) even if grossly resectable No requirement to open
        the pelvic peritoneum to define the extent of disease No extrapelvic nodal metastasis
        unless resected en bloc with the primary tumor No distant metastases No other diagnosis of
        stage II-III colon cancer within the past 5 years May have undergone complete surgical
        resection at least 5 years prior to study Completely resected prior or synchronous stage
        0-I colon cancer eligible

        PATIENT CHARACTERISTICS: Age: Adult Performance status: SWOG 0-2 Hematopoietic: WBC (white
        blood cell) at least 3,500/mm3 Platelet count at least within the lower limit of normal
        Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) AST (angiotensin
        sensitivity test) no greater than 2 times ULN Alkaline phosphatase no greater than 2 times
        ULN Renal: Creatinine no greater than 2 times ULN Other: No organic brain syndrome,
        Alzheimer's disease, or other altered mental status No second malignancy within 5 years
        except: Adequately treated nonmelanomatous skin cancer Adequately treated carcinoma in situ
        of the cervix Not pregnant or nursing Negative pregnancy test Effective contraception
        required of fertile patients

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
        fluorouracil or other chemotherapy for cancer No concurrent chemotherapy Endocrine therapy:
        Not specified Radiotherapy: No prior or concurrent radiotherapy for cancer Surgery:
        Complete en bloc resection required (see Disease Characteristics)
Clinical trial NCT00624286 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: indacaterol 150 μg, placebo to indacaterol
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

        • Male or female patients aged 40 years or over with moderate to severe chronic obstructive
        pulmonary disease (COPD) plus

          -  20 pack-year smoking history

          -  Signed informed consent

          -  Post-bronchodilator forced expiratory volume in 1 second )FEV1) ≥ 30% and < 80%
             predicted FEV1/FVC (forced vital capacity) < 70%

        Exclusion Criteria include:

          -  History of asthma

          -  Prior exposure to indacaterol

          -  Active cancer or history of cancer

          -  Patients with concomitant pulmonary disease

          -  Patients with diabetes Type I or uncontrolled diabetes Type II

          -  Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured
             at screening or randomization is prolonged

          -  Patients unable to successfully use a dry-powder inhaler device or perform spirometry
             measurements

        Other protocol-defined inclusion/exclusion criteria applied to the study.
Clinical trial NCT00051441 (phase 3, status: completed)
Conditions: stomatitis, radiation effects
ICD codes: B08.61, B37.0, A69.0, K12.1, B08.4
Drugs: benzydamine hydrochloride 0.15% oral rinse
SMILES: CN(C)CCCOC1=NN(CC2=CC=CC=C2)C2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Karnofsky performance scale >= 60%

          -  Diagnosis of pathologically confirmed malignancy involving one or more of the
             following sites: oral cavity, oropharynx extending down to the level of the
             supraglottic area, nasopharynx, maxillary sinus and parotid gland

          -  high risk for developing oral and/or oropharyngeal mucositis due to radiation to head
             and neck areas

          -  scheduled to receive a continuous course (eg, often six to eight weeks) of
             conventional or hyperfractionated external beam radiation for cancer of the head and
             neck region (subjects who had surgery prior to radiation are eligible) with or without
             concomitant chemotherapy

          -  at least two oral tissue sites (not including areas of previous lesions, tumor,
             surgical resection, or the lips) must be included in the RT treatment volume and
             planned to receive a total radiation dose of 5500 cGy or higher, given in a single
             daily fraction of 180 to 220 cGy or twice daily fractions of 110 to 150 cGy

        Exclusion Criteria:

          -  Known hypersensitivity to benzydamine HCl and/or any of the other components including
             alcohol, menthol, glycerin, flavoring agents, and preservatives

          -  oral or oropharyngeal mucositis present at the time of entry into the study

          -  treatment regimen consisting of noncontinuous radiation therapy

          -  received chemotherapy within 21 days of entry into the study as defined by initiation
             of radiation

          -  scheduled to receive or have received brachytherapy

          -  chronically being medicated for conditions other than tumor-related pain with oral
             and/or parenteral prescription steroids or analgesics

          -  use of chlorhexidine gluconate (Peridex), amifostine (Ethyol), topical antibiotics to
             the mouth (ie, tetracycline), topical steroids to the mouth, povidone iodine rinses,
             glutamine oral rinses, selective decontamination, and Granulocyte Macrophage-Colony
             Stimulating Factor (GM-CSF)

          -  use of mouthwash containing other exclusionary medications and any other medication(s)
             without an approved indication for topical oral use with the exception of liquid
             antacid formulations (eg, Maalox, Mylanta)

          -  participated in an investigational study within 30 days prior to enrolling into the
             study where an experimental drug and/or product was taken

          -  not willing and/or able to take opioids for any reason

          -  cryotherapy (ie, ice chips or popsicles) prior to or during chemotherapy infusion
Clinical trial NCT00120393 (phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: atazanavir/ritonavir +2 nrtis (immediate switch group), lpv/r +2 nrtis (delayed/optional switch group)
SMILES: COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  HIV positive

          -  LPV/RTV-based HAART for at least 6 months

          -  HIV-1 RNA less than 50c/mL (confirmed)

          -  Non-HDL higher than 160 mg/dL

          -  CD4 of at least 50 cells/mL

        Exclusion Criteria:

          -  Use of lipid-lowering agents
Clinical trial NCT00632866 (phase 3, status: completed)
Conditions: primary sjögren's syndrome
ICD codes: D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0
Drugs: hydroxychloroquine, placebo
SMILES: CCN(CC)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Patients suffering from primary Sjögren's syndrome according to the European-American
             consensus group criteria

          -  Male and female aged of 18 or more

          -  Conducting a clinical examination beforehand.

          -  Having undergone less than 6 months before an ophthalmological examination, which did
             not counter-indicated hydroxychloroquine.

          -  Patient without heart conduction disturbance (PR>=0.2 sec and QRS>=0.08 sec).

          -  Patient with the ability to give informed, dated and signed consent before the
             beginning of any proceedings related to the trial

          -  Patients treated with corticosteroids and / or NSAIDs, and / or cyclosporine, and / or
             pilocarpine must have received stable doses of these treatments during the month
             preceding inclusion.

        Exclusion criteria:

          -  SJ associated with other autoimmune diseases

          -  Retinopathy /severe cataract/ monophthalmos

          -  Previous or ongoing treatment by hydroxychloroquine

          -  Treatment by another immunosuppressant not interrupted at least 4 weeks prior to
             inclusion, or 6 months prior to inclusion for cyclophosphamide or rituximab

          -  lymphoma or other severe SJp complications: vasculitis responsible for a documented
             renal, neurological, digestive or heart involvement, glomerular disease associated
             with hematuria and / or proteinuria > 0.5 g / d), CNS involvement, peripheral
             neurological involvement with motor deficiency scored at 3 or less on a scale of 5 ,
             interstitial pneumonitis, recent symptomatic cryoglobulinemia with neurological,
             renal, or other systemic involvement, myositis with motor deficiency (isolated purpura
             is not an exclusion criteria)

          -  Chronic Alcoholism

          -  Hepato-cellular insufficiency

          -  Creatinine clearance <60 ml / min

          -  Risk of lost follow-up

          -  People younger than 18, major trusteeship and guardianship, or deprived of liberty

          -  Pregnancy /Breastfeeding

          -  Hypersensitivity to chloroquine or to hydroxychloroquine or any of the other
             constituents of Plaquenil

          -  Psoriasis or intermittent porphyria.

          -  G6PD deficiency, congenital galactosemia, malabsorption syndrome, glucose and
             galactose, or lactase deficiency.

          -  Non-membership in a social security system.
Clinical trial NCT00336713 (phase 3, status: completed)
Conditions: depressive disorder
ICD codes: F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9
Drugs: saredutant (sr48968c), placebo
SMILES: CN(C[C@@H](CCN1CCC(CC1)(NC(C)=O)C1=CC=CC=C1)C1=CC=C(Cl)C(Cl)=C1)C(=O)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of major depressive disorder, as defined by Diagnostic and Statistical
             Manual of Mental Disorders 4th edition (DSM-IV) criteria and confirmed by the
             semi-structured Mini International Neuropsychiatric Interview (MINI), recurrent
             episode.

        Exclusion Criteria:

          -  Total score of 28 or less on the Montgomery and Asberg Depression Rating Scale
             (MADRS).

          -  Clinical Global Impression (CGI) severity score of less than 4.

          -  Duration of the current depressive episode less than 2 months or greater than 2 years.

          -  Elderly patients with a Mini-Mental State Examination (MMSE) total score <25.

          -  Patients with a history or presence of bipolar disorders or psychotic disorders.

          -  Patients with alcohol dependence or abuse or substance dependence or abuse in the past
             12 months except nicotine or caffeine dependence.

          -  Benzodiazepine or sedative-hypnotic use greater than 2 days per week during the month
             prior to entry into the Acute Phase.

          -  Patients who have used the following prior to entry into Acute Phase: antipsychotics
             within 3 months, fluoxetine within 1 month, Monoamine oxidase inhibitors (MAOIs)
             within 2 weeks, other antidepressant or mood-stabilizer (lithium, anticonvulsants)
             within 1 week.

        The investigator will evaluate whether there are other reasons why a patient may not
        participate.
Clinical trial NCT00574249 (phase 3, status: completed)
Conditions: chronic plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: calcipotriol/betamethasone ointment, placebo (vehicle ointment)
SMILES: [H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is >= 18 years of age

          -  Subject had a clinical diagnosis of chronic plaque psoriasis for at least 6 months,
             and has moderate to severe plaque psoriasis

          -  Subject must have been treated and failed to respond to, or has a contraindication to,
             or is intolerant to at least two different systemic therapies, one of which must be
             cyclosporine, or methotrexate or oral PUVA

          -  Subject is judged to be in generally good health as determined by the principal
             investigator

        Exclusion Criteria:

          -  Subject has previous exposure to adalimumab

          -  Subject cannot discontinue systemic therapies and/or topical therapies for the
             treatment of psoriasis and cannot avoid UVB or PUVA phototherapy

          -  Subject is taking or requires oral or injectible corticosteroids

          -  Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced
             or medication-exacerbated psoriasis or new onset guttate psoriasis

          -  Subject considered by the investigator, for any reason, to be an unsuitable candidate

          -  Female subject who is pregnant or breast-feeding or considering becoming pregnant

          -  Subject has a calcium metabolism disorder
Clinical trial NCT01682720 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: sof, rbv, placebo to match sof, placebo to match rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age > 18 with chronic genotype 2 or 3 HCV infection

          -  HCV RNA > 10,000 IU/mL at screening

          -  Subjects must be treatment naive or treatment experienced

          -  Presence or absence of cirrhosis; a liver biopsy may be required

          -  Healthy according to medical history and physical examination with the exception of
             HCV diagnosis

          -  Agree to use two forms of highly effective contraception for the duration of the study
             and 6 months after the last dose of study medication

        Exclusion Criteria:

          -  Prior use of any other inhibitor of the HCV NS5B Polymerase

          -  History of any other clinically significant chronic liver disease

          -  Evidence of or history of decompensated liver disease

          -  HIV or chronic hepatitis B virus (HBV) infection

          -  Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved
             skin cancers)

          -  Chronic use of immunosuppressive agents or immunomodulatory agents

          -  History or current evidence of any condition, therapy, laboratory abnormality or other
             circumstance that might confound the results of the study, or interfere with the
             subject's participation for the full duration of the study or not be in the best
             interest of the subject in the opinion of the investigator
Clinical trial NCT00700427 (phase 3, status: completed)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: atomoxetine hydrochloride, placebo
SMILES: CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adults

          -  Male or female

          -  Must meet Attention-Deficit/Hyperactivity Disorder (ADHD) according to Diagnostic and
             Statistical Manual of Mental Disorders, Fourth Edition Text Revision™ (DSM-IV-TR™)
             criteria

        Exclusion Criteria:

          -  Comorbidity with major psychiatric disorder

          -  Clinically significant depression or anxiety

          -  Patients with significant medical conditions

          -  Current alcohol/drugs abuse/dependence

          -  Concomitant excluded medications
Clinical trial NCT00454337 (phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: ftc/tdf + efv or lpv/r +t20, ftc/tdf + efv or lpv/r
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic HIV-1 infection

          -  Treatment with a well-tolerated combination of antiretroviral drugs unchanged for at
             least 3 months, including enfuvirtide

          -  Absence of any uncontrolled opportunistic disease

          -  No restrictions on CD4 lymphocyte levels

          -  Plasma HIV-1 RNA below 400 copies per ml for at least 3 months (at least two
             consecutive tests below 400 copies per ml prior to inclusion in the study, not
             including that on W -4)

          -  For women of childbearing age, use of mechanical contraception during any sexual
             intercourse and negative pregnancy test (plasma ß HCG) at W -4

        Exclusion Criteria:

          -  HIV-2 infection

          -  Plasma HIV-1 RNA levels above 400 copies/ml on one occasion during the 3 months prior
             to screening (or the pre-inclusion visit at W -4)

          -  Poor compliance with antiretroviral therapy current at W -4

          -  Current treatment with an investigational drug (except cohort ATU)

          -  Patient previously treated with an integrase inhibitor in the context of a clinical
             study

          -  Woman who is pregnant or likely to become so, is breastfeeding or refuses to use
             contraception

          -  Multiple drug therapy ongoing or necessary in the foreseeable future for Kaposi's
             disease or lymphoma

          -  Treatment with interferon ongoing or necessary in the foreseeable future for chronic
             hepatitis B or C

          -  Acute hepatitis whatever the case, or decompensated cirrhosis

          -  Current treatment with interferon, interleukin or anti-HIV vaccine

          -  Any condition (including, but not limited to, the consumption of alcohol or drugs)
             which might, in the investigator's opinion, compromise the safety of treatment and/or
             patient compliance with the protocol

          -  Significant biological abnormalities (hemoglobin below 8g per dl, polynuclear
             neutrophils below 750 per mm3, platelets below 50,000 per mm3, serum creatinine above
             3 times the level deemed normal by the laboratory (N), ASAT or ALAT above 5N, serum
             lipase above 2N) and total bilirubin above 2N (except if the patient is receiving
             atazanavir or indinavir)

          -  Concomitant treatments including one or more compounds interacting with UGT1A1

               -  anti-infective agents: rifampicin/rifampin

               -  psychotropic/anti-epileptic drugs: phenytoin, phenobarbital.
Clinical trial NCT01213017 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: certolizumab pegol
SMILES: OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  moderate to severe RA (DAS > 4.4)

          -  at least two swollen and tender joints in one of the hand/ wrist

          -  patients must have failed at least one non-biologic or biologic DMARDs

          -  currently receiving MTX therapy

        Exclusion Criteria:

          -  concomitant diseases or pathological conditions that could interfere and impact the
             assessment of the study treatment
Clinical trial NCT00334828 (phase 3, status: completed)
Conditions: severe sepsis
ICD codes: R65.20, R65.21
Drugs: eritoran tetrasodium, placebo
SMILES: [H]\C(CCCCCC)=C(/[H])CCCCCCCCCC(O)=N[C@@]1([H])[C@]([H])(OC[C@@]2([H])O[C@]([H])(OP(O)(O)=O)[C@]([H])(N=C(O)CC(=O)CCCCCCCCCCC)[C@@]([H])(OCCCCCCCCCC)[C@]2([H])O)O[C@]([H])(COC)[C@@]([H])(OP(O)(O)=O)[C@]1([H])OCC[C@@]([H])(CCCCCCC)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        INCLUSION CRITERIA:

          -  Age >= 18 years

          -  Confirmed early-onset severe sepsis, defined as:

             o---Objective evidence of infection likely to be caused by a bacterial or fungal
             pathogen

             o---Presence of at least 3 of 4 systemic inflammatory response syndrome (SIRS)
             criteria

             o---Sepsis-associated organ dysfunction

          -  Baseline Acute Physiology and Chronic Health Evaluation II (Apache II) Score of 21 to
             37

          -  < 12 hours between onset of the first qualifying organ dysfunction and expected
             administration of study drug

          -  A commitment to full patient support

        EXCLUSION CRITERIA:

          -  Pregnancy or breastfeeding

          -  Extensive (>20% Body Surface Area) third-degree burns

          -  Weight > 150 kg at admission

          -  Patients whose death from sepsis is considered imminent

          -  Patients not expected to survive for at least 2 months due to a pre-existing and
             uncorrectable medical condition, or those in a chronic vegetative state

          -  Patients with severe congestive heart failure

          -  Patients currently receiving immunosuppressive therapy such as cyclosporine,
             azathioprine, or cancer chemotherapy

          -  Patients with granulocyte counts < 1000/mm^3 unless the decreased count is believed to
             be due to sepsis

          -  Patients that required cardiopulmonary resuscitation in the 4 weeks prior to
             evaluation for enrollment

          -  Human immunodeficiency virus (HIV)-positive patients with CD4 count <= 50/mm^3 within
             4 weeks of enrollment, or end-stage processes

          -  Patients with significant hepatic impairment, portal hypertension, or esophageal
             varices

          -  Patients who are expected to be treated with endotoxin-removal devices

          -  Patients with active cancer

          -  Patients receiving polymyxin B or colistin